335 results about "Nicotinamide mononucleotide" patented technology

The invention provides a nicotinamide ribokinase mutant and application thereof. Compared with an amino acid sequence SEQID NO. 2, the difference of the amino acid sequence of the mutant is that the D45th, D58th, R161th and Y164 sites in the amino acid sequence SEQID NO. 2 are subjected to single mutation or in-pair combined mutation or three combined mutation or four combined mutation. Novel nicotinamide ribokinase mutant industrial enzyme is used for synthesis and preparation of beta-nicotinamide mononucleotide. The constructed nicotinamide ribokinase mutant enzyme has the advantages that the enzyme cost is low, the transformation time is short, and the process operation is simple, and has a broad large-scale industrial application prospect.

The invention discloses a niacinamide ribose phosphate transferase for preparing NMN, a coding gene, a recombinant vector and application and belongs to the technical field of biology. The transferaseis protein of which the amino acid sequence is shown in pSEQ ID No.1 or pSEQ ID No.2 or pSEQ ID No.3 or pSEQ ID No4. The gene for coding the protein is cloned to an expression vector of escherichia coli, and a recombinant plasmid is established; then, the recombinant plasmid is converted into escherichia coli competent cells, a positive clone is selected, an expression strain of recombinant escherichia coli is obtained, and then liquid fermentation is conducted; in the fermentation process, the generated recombinant niacinamide ribose phosphate transferase is generated, and after a substrateis added, beta-nicotinamide mononucleotide can be generated. According to the transferase, NMN is conveniently and efficiently prepared, the fermentation technology is simple, the consumed time is short, the cost is low, the cost of obtaining NMN is 0.25-1.0 yuan/mg, compared with a traditional method, the cost can be lowered by above 90%, the yield reaches 51.75 mg/g of protein, and the economicbenefit is obvious.

A medication having nicotinamide mononucleotide as the active ingredient, and the use of nicotinamide mononucleotide in preparing medications for the prevention and treatment of arteriosclerosis and cardiovascular and cerebrovascular diseases caused by arteriosclerosis.